Polyclonal Intestinal Tumors: Formation, Progression, and Significance
多克隆肠肿瘤:形成、进展和意义
基本信息
- 批准号:8225175
- 负责人:
- 金额:$ 29.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-01 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenocarcinomaAdenomatous Polyposis ColiAllelesAzoxymethaneBenignCaliberCancer BiologyCancer EtiologyCell LineageCellsCellular StructuresCessation of lifeChemopreventionClonal ExpansionColonic NeoplasmsColorectal CancerConsensusDataDatabasesDevelopmentDiseaseDrug Delivery SystemsEthylnitrosoureaGrowthHealthHumanImageImage AnalysisImaging TechniquesIndividualInterventionIntestinal CancerIntestinal NeoplasmsIntestinesKaryotypeMalignant NeoplasmsMediatingMediator of activation proteinModelingMonitorMusMutationNaturePathway interactionsPharmaceutical PreparationsPopulationResearch PersonnelScienceSignal PathwaySignaling MoleculeStem cellsStructureTechniquesTechnologyTestingTimeTissue BankingTissue BanksTumor-DerivedUnited StatesWorkadenomaanticancer researchchemotherapydesignexperiencegenetic manipulationinterestmalignant statemouse modelneoplastic cellprogenitorresearch studytumortumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Colorectal cancer is a leading cause of cancer death in the United States. Many investigators believe that a tumor is derived from a single abnormal progenitor and its descendents. The data supporting this long-held view are neither extensive nor definitive. Moreover, the experimental techniques used were heavily biased. We believe that a tumor is derived from multiple abnormal progenitors because clonal interactions among these cells provide a selective advantage during formation, growth, and progression. This hypothesis will be tested using a unique combination of newly developed mouse models, statistical analyses, and imaging techniques. We will analyze tumors from mice treated with either ethylnitrosourea (ENU) or azoxymethane (AOM), mice in which Apc is inactivated somatically by silencing, and mice in which tumorigenesis is initiated because of a mutation in the TGF2 signaling pathway (Aim 1). If polyclonality provides a selective advantage, heterotypic tumors should be common among these distinct mouse models. The tumors will be maintained in a tissue bank that will be well documented using an Access database. We will explore how heterotypic tumors emerge (Aim 2). Our initial study indicates that the most likely explanation involves clonal interactions occurring over very short distances. We will test whether polyclonality persists as tumors grow and progress from benign to malignant states (Aim 3). The results from our proposed experiments could fundamentally change the understanding of tumorigenesis in the mammalian intestine. The acceptance of this new view will undoubtedly impact the design of approaches for chemoprevention and chemotherapy. Signaling molecules mediating clonal interactions would likely be ideal targets for drug intervention. Potential mediators can be first examined utilizing our tissue bank of highly characterized tumors from a variety of mouse models. Each candidate that is still deemed interesting can then be fully tested using our experimental platform, i.e., one could determine whether elimination of the candidate through either drug intervention or genetic manipulation completely impairs the formation, growth, or progression of polyclonal tumors. PUBLIC HEALTH RELEVANCE: Initial studies from us and others indicate early adenomas are often derived from multiple progenitors, i.e., these tumors are polyclonal, not monoclonal as long believed by many investigators. Polyclonal tumors appear to emerge because of interactions occurring over very short distances. We extend our initial study by answering several fundamental questions regarding polyclonality using a unique combination of newly developed mouse models, statistical analyses, and imaging platforms. A deep understanding of this issue will likely impact the development of management strategies for intestinal cancer.
描述(由申请人提供):结直肠癌是美国癌症死亡的主要原因。许多研究人员认为,肿瘤是由一个异常的祖先和它的后代。支持这一长期观点的数据既不广泛也不明确。此外,所使用的实验技术存在严重偏差。我们认为肿瘤是由多种异常祖细胞产生的,因为这些细胞之间的克隆相互作用在形成、生长和进展过程中提供了选择性优势。将使用新开发的小鼠模型、统计分析和成像技术的独特组合来检验这一假设。我们将分析来自用乙基亚硝基脲(ENU)或氧化偶氮甲烷(AOM)治疗的小鼠的肿瘤,其中Apc通过沉默体细胞失活的小鼠,以及由于TGF 2信号通路突变而引发肿瘤发生的小鼠(Aim 1)。如果多克隆性提供了选择性优势,那么异型肿瘤在这些不同的小鼠模型中应该是常见的。将肿瘤保存在组织库中,并使用Access数据库进行充分记录。我们将探讨异型肿瘤是如何出现的(目标2)。我们的初步研究表明,最可能的解释涉及克隆相互作用发生在非常短的距离。我们将测试多克隆性是否随着肿瘤的生长和从良性到恶性状态的进展而持续(目标3)。我们提出的实验结果可能从根本上改变对哺乳动物肠道肿瘤发生的理解。这一新观点的接受无疑将影响化学预防和化学治疗方法的设计。介导克隆相互作用的信号分子可能是药物干预的理想靶点。可以首先利用我们的组织库从各种小鼠模型高度表征的肿瘤检查潜在的介质。每个仍然被认为有趣的候选人可以使用我们的实验平台进行全面测试,即,可以确定通过药物干预或遗传操作消除候选物是否完全损害多克隆肿瘤的形成、生长或进展。公共卫生相关性:我们和其他人的初步研究表明,早期腺瘤通常来源于多个祖细胞,即,这些肿瘤是多克隆的,而不是许多研究者长期认为的单克隆的。多克隆肿瘤的出现似乎是因为在很短的距离内发生的相互作用。我们通过使用新开发的小鼠模型,统计分析和成像平台的独特组合来回答有关多克隆性的几个基本问题,从而扩展了我们的初步研究。对这一问题的深入了解可能会影响肠癌管理策略的制定。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard Brott Halberg其他文献
Richard Brott Halberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard Brott Halberg', 18)}}的其他基金
Features of the early adenoma and adjacent colon that drive progression: the role of mutation burden in normal tissue, senescent cells, and tumor clonal architecture
驱动进展的早期腺瘤和邻近结肠的特征:突变负荷在正常组织、衰老细胞和肿瘤克隆结构中的作用
- 批准号:
10707105 - 财政年份:2022
- 资助金额:
$ 29.89万 - 项目类别:
Features of the early adenoma and adjacent colon that drive progression: the role of mutation burden in normal tissue, senescent cells, and tumor clonal architecture
驱动进展的早期腺瘤和邻近结肠的特征:突变负荷在正常组织、衰老细胞和肿瘤克隆结构中的作用
- 批准号:
10519075 - 财政年份:2022
- 资助金额:
$ 29.89万 - 项目类别:
Molecular Differences Predicting Tumor Progression in Colorectal Cancer (PQ #14)
预测结直肠癌肿瘤进展的分子差异(PQ
- 批准号:
8538333 - 财政年份:2012
- 资助金额:
$ 29.89万 - 项目类别:
Molecular Differences Predicting Tumor Progression in Colorectal Cancer (PQ #14)
预测结直肠癌肿瘤进展的分子差异(PQ
- 批准号:
8384609 - 财政年份:2012
- 资助金额:
$ 29.89万 - 项目类别:
Polyclonal Intestinal Tumors: Formation, Progression, and Significance
多克隆肠肿瘤:形成、进展和意义
- 批准号:
7766296 - 财政年份:2009
- 资助金额:
$ 29.89万 - 项目类别:
Polyclonal Intestinal Tumors: Formation, Progression, and Significance
多克隆肠肿瘤:形成、进展和意义
- 批准号:
7652563 - 财政年份:2009
- 资助金额:
$ 29.89万 - 项目类别:
Polyclonal Intestinal Tumors: Formation, Progression, and Significance
多克隆肠肿瘤:形成、进展和意义
- 批准号:
8446525 - 财政年份:2009
- 资助金额:
$ 29.89万 - 项目类别:
Polyclonal Intestinal Tumors: Formation, Progression, and Significance
多克隆肠肿瘤:形成、进展和意义
- 批准号:
8033178 - 财政年份:2009
- 资助金额:
$ 29.89万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 29.89万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 29.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 29.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 29.89万 - 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 29.89万 - 项目类别:
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 29.89万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 29.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 29.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 29.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 29.89万 - 项目类别:














{{item.name}}会员




